BeaconDx

Biotechnology Research • • 1-10 Employees

Company overview

Headquarters	XX
NAICS	541714
Employees	1-10

Key Contact at BeaconDx

Robyn Schlicher

Co-Founder & CEO

About BeaconDx

At Beacon Dx our goal is to change the way care is managed for patients suffering from viral and bacterial infections across the broad spectrum of potential outcomes, from long term illness (Long-COVID) to acute and potentially terminal infections Our blood-based diagnostic platform is a matrix capable of capturing specific proteins in the blood to indicate immune status from possible exposure to infectious agents, known as MENSA (Media Enriched by Newly Synthesized Antibodies). These antibodies act as a “snapshot" of current immune system reactivity. The MENSA platform sheds light on whether current symptoms are potentially caused by both current or past infection, even if the initial infection was months prior, like those experienced by Long-COVID patients

BeaconDx revenue & valuation

Annual revenue	$85,555
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$273,776
Total funding	No funding